<DOC>
	<DOCNO>NCT00126139</DOCNO>
	<brief_summary>The purpose present prospective , randomize , double-blind , double dummy control multicenter pilot study investigate whether abciximab , compare aspirin , able reduce rate recurrent ischemic stroke carotid endarterectomy [ CEA ] ( primary endpoint ) ; degree carotid stenosis , number microembolic signal ( MES ) count , number ischemic infarct diffusion weight imaging ( DWI ) amount intraluminal thrombus pathological examination ( secondary endpoint ) patient ischemic stroke due &gt; 50 % carotid stenosis undergo CEA .</brief_summary>
	<brief_title>Abciximab Prevention Stroke Recurrence Before Endarterectomy Symptomatic Carotid Stenosis</brief_title>
	<detailed_description>Prospective randomize trial show carotid endarterectomy ( CEA ) beneficial stroke prevention symptomatic severe moderate stenosis carotid artery . Medical treatment timing CEA recent stroke due carotid narrowing , however , remain controversial . Prospective , placebo-controlled acute stroke trial either screen exclude carotid stenosis . The early experience CEA result generally accept policy delay surgery 4 6 week fear clinical deterioration associate conversion bland hemorrhagic infarction . Subsequent study suggest endarterectomy need necessarily postpone patient nondisabling stroke , confirm Giordano . Furthermore , patient recover fast enough allow early carotid surgery nondisabling stroke . The risk recurrent stroke wait 4 6 week CEA 9.5 % 74 prospectively studied patient 21 % retrospective series 19 patient . Similarly , 4.9 % 103 medically treated patient stroke severe carotid stenosis recurrent ipsilateral stroke within 30 day entry NASCET trial . Analogous coronary artery disease , carotid stenosis assume become symptomatic plaque fissure lead exposure content blood , platelet activation thrombosis may cause cerebral ocular embolus narrow vessel lumen . Therefore , administration drug , reduce amount carotid thrombosis thus stabilize plaque would expect reduce risk recurrent stroke progression carotid stenosis occlusion , allow postpone CEA . Furthermore , also intraoperative ischemic stroke due cerebral embolus arise friable plaque dissection cross-clamping carotid artery may decrease . Prospective percutaneous coronary revascularization trial use balloon angioplasty , stenting atherectomy patient ischemic heart disease show addition abciximab , blocker platelet glycoprotein ( GP ) IIb/IIIa receptor , intervention reduce rate thrombotic complication , particularly myocardial infarction , death within 30 day . Symptomatic intracranial hemorrhage ( ICH ) occur 0.0-0.1 % 2535 patient treat abciximab , medium-dose aspirin , low-dose heparin endovascular procedure . Endovascular coronary intervention disrupt dissect arterial wall , lead exposure plaque content component vascular wall blood , result platelet activation thrombosis . Interestingly , also abciximab give 18 24 hour prior intervention reduce rate thrombotic event suggest stabilization coronary plaque . A recent prospective , placebo-controlled safety pilot efficacy trial abciximab 74 patient acute ischemic stroke treat within 24 hour symptom onset find abciximab cause symptomatic ICH show trend toward high rate patient minimal residual disability . Thus , abciximab may attractive therapy option prevent stroke recurrence patient embolic carotid territory stroke due carotid stenosis . The number microembolic signal ( MES ) detect middle cerebral artery ( MCA ) downstream symptomatic carotid stenosis transcranial Doppler sonography ( TCD ) show predict stroke risk , dramatically reduce patient acute ischemic stroke cause carotid artery disease administration GP IIb/IIIa inhibitor tirofiban . These data suggest monitoring MES MCA distal symptomatic carotid stenosis administration abciximab may useful surrogate marker assess efficacy drug prevent MES stroke patient symptomatic carotid stenosis . Diffusion-weighted MR imaging ( DWI ) high sensitivity detect acute brain ischemia , recent DWI study assess incidence asymptomatic ischemic brain lesion patient underwent CEA . The purpose present prospective , randomize , double-blind , double dummy control multicenter pilot study investigate whether abciximab compare aspirin able reduce rate recurrent ischemic stroke CEA ( primary endpoint ) , degree carotid stenosis , number MES count , number ischemic infarct DWI amount intraluminal thrombus pathological examination ( secondary endpoint ) patient ischemic stroke due &gt; 50 % carotid stenosis undergo CEA .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Carotid Stenosis</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Age least 18 year . Presence symptom ischemic stroke baseline National Institutes Health Stroke Scale ( NIHSS ) scale one 20 due ipsilateral atherosclerotic &gt; 50 % stenosis extracranial internal carotid artery ( ICA ) show ultrasonography . Latency onset stroke symptom intend administration study drug 24 hour . Latency intend administration study drug intend carotid endarterectomy least three day . Documented peptic ulcer disease within precede 30 day . Septicemia severe localize infection . Severe illness ( active cancer significant liver renal disease ) disability . Alcohol illicit drug abuse . Pregnancy . Need chronic anticoagulant therapy ( e.g . atrial fibrillation , deep venous thrombosis ) . Need longterm daily nonsteroidal antiinflammatory drug . Contraindications platelet therapy severe bleed disorder within past three month prior randomization ( coagulopathy , platelet disorder include history heparininduced thrombopenia , hemorrhage ) significant retinopathy hemorrhage exudate . Hypersensitivity abciximab , murine monoclonal antibody aspirin . Any preexist intracranial neurological disease tumor multiple sclerosis . Intracranial intraspinal operation trauma lumbar puncture within last 2 month . Cardiac lesion likely cause cardioembolism . Suspicion establish nonatherosclerotic carotid artery disease dissection vasculitis ( Takayasu disease , giant cell arteritis , significant collagen vascular disease , systemic necrotizing vasculitis , granulomatous angiitis nervous system ) . Participation another acute stroke trial investigate drug abciximab . Treatment present stroke tissue plasminogen activator , urokinase ancrod . ICH , aneurysm , vascular malformation arteriovenous fistula sinovenous thrombosis brain . Brain infarct involve whole territory middle cerebral artery ( MCA ) . Stupor coma . Uncontrolled hypertension ( systolic pressure &gt; 200 mmHg and/or diastolic pressure &gt; 110 mmHg ) . No informed consent . Contraindication undergo magnetic resonance ( MR ) imaging ( eg pacemaker ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stroke , ischemic</keyword>
	<keyword>stenosis , internal carotid artery</keyword>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Stenosis extracranial internal carotid artery</keyword>
</DOC>